SEAGEN IS HERE TO HELP YOUR PATIENTS ACCESS TUKYSA

Seagen Secure® logo with description “Patient Assistance Program”

Seagen Secure® is a comprehensive, personalized reimbursement support program for TUKYSA

Seagen Secure® can help your patients navigate treatment by offering individualized assistance.
Enroll Now

How to fill a TUKYSA prescription

TUKYSA (tucatinib) prescriptions are filled through specialty pharmacies in the TUKYSA network or through dispensing physician practices and hospital pharmacies that can purchase the product through their specialty distributors.

SPECIALTY PHARMACIES

  • Biologics
  • Onco360

IN-OFFICE DISPENSERS

(MEDICALLY INTEGRATED
DISPENSARIES)

 

IDN SPECIALTY PHARMACIES AND HOSPTIAL PHARMACIES

Physician practices can obtain TUKYSA from one of the following specialty distributors

TUKYSA dosage strengths and counts

TUKYSA dosage strengths and counts: 50mg tablets 60 count in 75 cc bottle
50 mg
60 count in 75 cc bottle
NDC 51144-001-60
TUKYSA dosage strengths and counts: 150mg tablets 60 count in 75 cc bottle
150 mg
60 count in 75 cc bottle
NDC 51144-002-60
TUKYSA dosage strengths and counts: 150mg tablets 120 count in 150 cc bottle
150 mg
120 count in 150 cc bottle
NDC 51144-002-12

These Specialty Pharmacies are authorized to dispense TUKYSA

Biologics by McKesson logo
CALL 800-850-4306
FAX 800-823-4506
VISIT biologics.mckesson.com
Onco360 Oncology Pharmacy logo
CALL 877-662-6633
FAX 877-662-6355
VISIT onco360.com

Insurance Coverage by Category

TUKYSA is covered by over 96.7% of US insurance providers.

  • Insurance Coverage by Category: Total
    Total
  • Insurance Coverage by Category: Commercial
    Commercial
  • Insurance Coverage by Category: Medicare
    Medicare
  • Insurance Coverage by Category: Medicaid
    Medicaid
  • Covered
  • Not Covered
  • Unknown
Unknown coverage means that MMIT was not able to determine coverage at the time of the analysis – this does not imply any coverage or lack of coverage for these patients. Data provided by MMIT – Coverage of TUKYSA pharmacy benefits as of 05/15/2023.
Email icon

Keep current on news and updates.

Sign up here
Next: Resource library

Important Safety Information

Warnings and Precautions

  • Diarrhea: TUKYSA can cause severe diarrhea including dehydration, hypotension, acute kidney injury, and death. If diarrhea occurs, administer antidiarrheal treatment as clinically indicated. Perform diagnostic tests as clinically indicated to exclude other causes of diarrhea. Based on the severity of the diarrhea, interrupt dose, then dose reduce or permanently discontinue TUKYSA.

    In HER2CLIMB, when TUKYSA was given in combination with trastuzumab and capecitabine, 81% of patients who received TUKYSA experienced diarrhea, including 0.5% with Grade 4 and 12% with Grade 3. Both patients who developed Grade 4 diarrhea subsequently died, with diarrhea as a contributor to death. Median time to onset of the first episode of diarrhea was 12 days and the median time to resolution was 8 days. Diarrhea led to TUKYSA dose reductions in 6% of patients and TUKYSA discontinuation in 1% of patients. Prophylactic use of antidiarrheal treatment was not required on HER2CLIMB.

  • Hepatotoxicity: TUKYSA can cause severe hepatotoxicity. Monitor ALT, AST, and bilirubin prior to starting TUKYSA, every 3 weeks during treatment, and as clinically indicated. Based on the severity of hepatotoxicity, interrupt dose, then dose reduce or permanently discontinue TUKYSA.

    In HER2CLIMB, 8% of patients who received TUKYSA had an ALT increase >5 × ULN, 6% had an AST increase >5 × ULN, and 1.5% had a bilirubin increase >3 × ULN (Grade ≥3). Hepatotoxicity led to TUKYSA dose reductions in 8% of patients and TUKYSA discontinuation in 1.5% of patients.

  • Embryo-Fetal Toxicity: TUKYSA can cause fetal harm. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential, and male patients with female partners of reproductive potential, to use effective contraception during TUKYSA treatment and for 1 week after the last dose.

Adverse Reactions

In HER2CLIMB, serious adverse reactions occurred in 26% of patients who received TUKYSA; the most common (in ≥2% of patients) were diarrhea (4%), vomiting (2.5%), nausea (2%), abdominal pain (2%), and seizure (2%). Fatal adverse reactions occurred in 2% of patients who received TUKYSA including sudden death, sepsis, dehydration, and cardiogenic shock.

Adverse reactions led to treatment discontinuation in 6% of patients who received TUKYSA; the most common (in ≥1% of patients) were hepatotoxicity (1.5%) and diarrhea (1%). Adverse reactions led to dose reduction in 21% of patients who received TUKYSA; the most common (in ≥2% of patients) were hepatotoxicity (8%) and diarrhea (6%).

The most common adverse reactions in patients who received TUKYSA (≥20%) were diarrhea, palmar-plantar erythrodysesthesia, nausea, hepatotoxicity, vomiting, stomatitis, decreased appetite, anemia, and rash.

Lab Abnormalities

In HER2CLIMB, Grade ≥3 laboratory abnormalities reported in ≥5% of patients who received TUKYSA were decreased phosphate, increased ALT, decreased potassium, and increased AST.

The mean increase in serum creatinine was 32% within the first 21 days of treatment with TUKYSA. The serum creatinine increases persisted throughout treatment and were reversible upon treatment completion. Consider alternative markers of renal function if persistent elevations in serum creatinine are observed.

Drug Interactions

  • Strong CYP3A/Moderate CYP2C8 Inducers: Concomitant use may decrease TUKYSA activity. Avoid concomitant use of TUKYSA.
  • Strong or Moderate CYP2C8 Inhibitors: Concomitant use of TUKYSA with a strong CYP2C8 inhibitor may increase the risk of TUKYSA toxicity; avoid concomitant use. Increase monitoring for TUKYSA toxicity with moderate CYP2C8 inhibitors.
  • CYP3A Substrates: Concomitant use may increase the toxicity associated with a CYP3A substrate. Avoid concomitant use of TUKYSA where minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is unavoidable, decrease the CYP3A substrate dosage.
  • P-gp Substrates: Concomitant use may increase the toxicity associated with a P-gp substrate. Consider reducing the dosage of P-gp substrates where minimal concentration changes may lead to serious or life-threatening toxicity.

Use in Specific Populations

  • Lactation: Advise women not to breastfeed while taking TUKYSA and for 1 week after the last dose.
  • Renal Impairment: Use of TUKYSA in combination with capecitabine and trastuzumab is not recommended in patients with severe renal impairment (CLcr < 30 mL/min), because capecitabine is contraindicated in patients with severe renal impairment.
  • Hepatic Impairment: Reduce the dose of TUKYSA for patients with severe (Child-Pugh C) hepatic impairment.

REF-7648_FINAL_01/23

Indication

TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.

Please see full Prescribing Information.